 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...4567891011121314...1920» |
- NT219 / Purple Biotech, foscenvivint (PRI-724) / PRISM Pharma, Ohara Pharma
Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2 (Section 13) - Mar 9, 2022 - Abstract #AACR2022AACR_3022;
Interestingly, β-catenin inhibition (using ICG-001) or IRS2 inhibition (using NT219) in IRS2-expressing cells decreased their viability, β-catenin transcriptional activity, and mitochondrial activity, suggesting involvement of IRS2 in modulating OXPHOS through β-catenin...These effects may be mediated, at least in part, by modulation of the β-catenin and OXPHOS pathway. Given the molecular signature described, the approach to patients with BM may be significantly impacted by agents such as NT219.
- || Erwinase (erwinia L-asparaginase) / Jazz
PK/PD data, Journal: Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. (Pubmed Central) - Mar 8, 2022
Given the molecular signature described, the approach to patients with BM may be significantly impacted by agents such as NT219. Overall, this next generation product PEG-nErA (with improved PK and PD characteristics compared to nErA) would bring a significant advantage to the therapeutic needs of ALL patients and should be further explored in clinical trials.
- | foscenvivint (PRI-724) / PRISM Pharma, Ohara Pharma
Journal: The Wnt Signaling Pathway Inhibitors Improve the Therapeutic Activity of Glycolysis Modulators against Tongue Cancer Cells. (Pubmed Central) - Mar 8, 2022
However, the inhibition of the canonical Wnt pathway by PRI-724 was more beneficial, based on the glycolytic activity of the cells. The results point to the therapeutic potential of the combination of low concentrations of glycolytic modulators with Wnt pathway inhibitors in oral cancer cells.
- | JPH203 - J / Pharma
Journal: Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells. (Pubmed Central) - Mar 5, 2022
Moreover, siRNA-mediated CTH knockdown induced oxidative stress in response to JPH203 leading to decreased cell viability in MDA-MB-231 cells. These results suggest that activation of anti-oxidation pathways in response to amino acid deprivation confers resistance to anti-LAT1 therapy.
- | foscenvivint (PRI-724) / PRISM Pharma, Ohara Pharma
Journal: Involvement of activator protein-1 family members in β-catenin and p300 association on the genome of PANC-1 cells. (Pubmed Central) - Feb 25, 2022
ICG-001 is a specific inhibitor for β-catenin/CBP but not for β-catenin/p300...Taken together, AP-1 possibly coordinates β-catenin coactivator usage in PANC-1 cells. These results would further our understanding of the canonical Wnt/β-catenin signaling divergence.
- || Jakafi (ruxolitinib) / Incyte
Trial primary completion date: AALL1521: A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 24, 2022
P2, N=170, Recruiting, Sponsor: Incyte Corporation
These results would further our understanding of the canonical Wnt/β-catenin signaling divergence. Trial primary completion date: Feb 2024 --> Dec 2024
- | foscenvivint (PRI-724) / PRISM Pharma, Ohara Pharma
Journal: Cannabinoid receptor 2 plays a central role in renal tubular mitochondrial dysfunction and kidney ageing. (Pubmed Central) - Feb 22, 2022
These results show CB2 plays a central role in renal tubular mitochondrial dysfunction and kidney ageing. The intrinsic mechanism may be related to its activation in β-catenin signalling.
- foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
PD-L1 Mediates Lung Fibroblast to Myofibroblast Transition Through Smad3 and GSK3beta/Beta-Catenin Signaling Pathways (Area K, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_5000;
We found significantly increased PD-L1 in the lungs of idiopathic pulmonary fibrosis patients and mice with pulmonary fibrosis induced by bleomycin and TGF-β...Inhibiting β-catenin signaling with the pharmaceutical inhibitor ICG001 significantly attenuated TGF-β-induced FMT. Our findings demonstrate that fibroblast PD-L1 may promote pulmonary fibrosis through both Smad3 and GSK3β/β-catenin signaling and may represent a novel interventional target for IPF.
- | Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Trial primary completion date: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Feb 16, 2022
P1, N=32, Recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Our findings demonstrate that fibroblast PD-L1 may promote pulmonary fibrosis through both Smad3 and GSK3β/β-catenin signaling and may represent a novel interventional target for IPF. Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Sep 2021 --> Sep 2022
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Trial primary completion date: NANT 2013-01: Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells (clinicaltrials.gov) - Feb 16, 2022
P1, N=24, Recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Sep 2021 --> Sep 2022 Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Sep 2021 --> Sep 2022
- | ZSTK474 / Zenyaku Kogyo
Journal, IO biomarker: The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress. (Pubmed Central) - Feb 16, 2022
Finally, the xenograft tumor-bearing mice models were established, and the results showed that ZSTK474-VSVΔ51 combined treatment synergistically hindered tumorigenesis of osteosarcoma cells in vivo. Taken together, our data suggested that ZSTK474 was a novel agent to enhance the cytotoxic effects of VSVΔ51 on osteosarcoma by aggravating ER-stress, and the present study might provide alternative therapy treatments for osteosarcoma in clinic.
- || azacitidine / Generic mfg., decitabine / Generic mfg.
Clinical, Journal: Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism. (Pubmed Central) - Feb 15, 2022
Both genomic mutations might lead to loss of protein expression. Thus, inactivation of UCK2 and DCK might be a putative cause of phenotypes that are resistant to AZA and DAC/OR21, respectively.
- | foscenvivint (PRI-724) / PRISM Pharma, Ohara Pharma
Journal: Small Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Enhanced Proangiogenic Potential of Cardiac Fibroblasts via Angiopoietin-Like 4. (Pubmed Central) - Feb 15, 2022
The β-catenin inhibitor ICG001 was used to examine whether β-catenin was involved in the proangiogenic potential of CFs promoted by sEVs...The sEVs regulated CFs to promote angiogenesis via Angptl4 in an inflammatory environment. This may provide a research basis for treating myocardial injury with sEVs.
- | ZSTK474 / Zenyaku Kogyo
Journal: Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. (Pubmed Central) - Feb 8, 2022
Compounds 6r and 6s also demonstrated in vivo tolerability with therapeutic efficacy through reduction of kinase activation and amelioration of disease phenotypes in the JAK2V617F mutant myelofibrosis mouse cancer model. Taken together, these results support further structure optimization of 6r and 6s as promising leads for combination therapy in human cancer as a new class of PI3K/MEK bifunctional inhibitors.
- | OR-2100 / Ohara Pharma
Journal: Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. (Pubmed Central) - Feb 2, 2022
We investigated the efficacy of OR-2100 (OR21), the first orally available single-compound prodrug of decitabine...OR21 in combination with imatinib significantly suppressed tumor growth in a xenotransplant model...These results demonstrate that targeting DNMT1 using OR21 exerts anti-tumor effects and impairs LSCs in CML. Therefore, combination treatment of TKIs and OR21 represents a promising treatment strategy in CML.
- | humanised dinutuximab (Hu14.18K322A) / St. Jude Children's Research Hospital, Unituxin (dinutuximab) / United Therapeutics Corp
This improved, genetically modified version of Unituxan (dinutuximab), an approved monoclonal antibody (mAb) targeting the disialoganglioside GD2. It has a significantly better tolerance profile and is known as hu14.18K322A, which improved survival rates and outcomes. (Twitter) - Jan 28, 2022
- JPH203 - J / Pharma
Conformationally restricted derivatives of L-tyrosine and L-tryptophan as inhibitors of the L-type amino acid transporter LAT1 (Room 32B (San Diego Convention Center)) - Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_7336;
For several of the meta-l-tyrosine derived inhibitors, cryo-electron microscopy structures were obtained for the corresponding complexes with LAT1, showing the transporter in an outward-open conformation. The implications of these structural findings for the mechanism of transport by LAT1 will also be discussed.
- | JPH203 - J / Pharma
Biomarker, Journal: Expression of L-type amino acid transporter 1 is a poor prognostic factor for Non-Hodgkin's lymphoma. (Pubmed Central) - Jan 27, 2022
Furthermore, pharmacological inhibition of LAT1 by a specific inhibitor JPH203 inhibits lymphoma cell growth. In conclusion, our study demonstrated that LAT1 expression can be used as a prognostic marker for patients with NHL and targeting LAT1 by JPH203 can be a novel therapeutic modality for NHL.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction. (Pubmed Central) - Jan 26, 2022
Moreover, activated Wnt3α/β-catenin/GSK-3β signaling was inhibited by dapagliflozin and Wnt/β-catenin inhibitor ICG-001. Our findings suggest that dapagliflozin ameliorates renal fibrosis by inhibiting RIP1-RIP3-MLKL-mediated necroinflammation via Wnt3α/β-catenin/GSK-3β signaling in UUO.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma, magrolimab (ONO-7913) / Ono Pharma
Trial suspension: Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma (clinicaltrials.gov) - Jan 26, 2022
P1, N=82, Suspended, Sponsor: National Cancer Institute (NCI)
Our findings suggest that dapagliflozin ameliorates renal fibrosis by inhibiting RIP1-RIP3-MLKL-mediated necroinflammation via Wnt3α/β-catenin/GSK-3β signaling in UUO. Recruiting --> Suspended
- | PRI-724 / PRISM Pharma, Ohara Pharma
Journal: FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signaling pathway. (Pubmed Central) - Jan 18, 2022
We also found the WNT signaling pathway inhibitor ICG-001 can block HOXB13 gene-induced tumor metastasis, therefore ICG-001 may be a promising molecular intervention. This study provides insight into the relationship between obesity and the pathogenesis of endometrial cancer while highlighting future areas of research.
- || OR-2003 / Ohara Pharma
Learn from Taiwan. Or 2003. Or history in general. (Twitter) - Jan 15, 2022
- | PRI-724 / PRISM Pharma, Ohara Pharma
Journal: HOXA10 may inhibit the osteogenic differentiation of periodontal ligament stem cells by regulating β-catenin and DKK1. (Pubmed Central) - Jan 14, 2022
This study provides insight into the relationship between obesity and the pathogenesis of endometrial cancer while highlighting future areas of research. These data demonstrate that HOXA10 inhibits the osteogenic differentiation of periodontal ligament stem cells by regulating β-catenin localization and DKK1.
- | Amnolake (tamibarotene) / TMRC, Syros, Nippon Shinyaku, Zeria Pharma, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Journal: Refractory acute promyelocytic leukemia with a complex karyotype (Pubmed Central) - Jan 14, 2022
Since the coordination of the unrelated donor had been completed at this time, she then underwent bone marrow transplantation with pre-conditioning of 4 Gy total body irradiation, fludarabine, and busulfan...APL usually has a good prognosis, and relapsed cases are often cured by autologous stem cell transplantation. However, this case was highly refractory to treatment and the patient deteriorated rapidly after the transplantation, suggesting a different pathogenesis from the usual from of APL.
- | Unituxin (dinutuximab) / United Therapeutics Corp
Journal, IO biomarker: Development of a Dinutuximab Delivery System Using Silk Foams for GD2 Targeted Neuroblastoma Cell Death. (Pubmed Central) - Jan 13, 2022
Additionally, we observed that the effectiveness of CDC induction by DNX could be correlated to the GD2 expression level of the target cells, with both the intravenous DNX formulation and the released DNX. Collectively, this data highlights a strategy to overcome delivery challenges and potentially improve therapeutic efficacy in cells expressing heterogenous levels of GD2.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Anktiva (inbakicept) / ImmunityBio
Preclinical, Journal, IO biomarker: Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2 pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. (Pubmed Central) - Jan 12, 2022
Collectively, this data highlights a strategy to overcome delivery challenges and potentially improve therapeutic efficacy in cells expressing heterogenous levels of GD2. Our results provide the rationale for the development of a clinical trial of N-803 in combination with dinutuximab and ex vivo exPBNK cells in patients with recurrent or metastatic GD2 solid tumors.
- | Unituxin (dinutuximab) / United Therapeutics Corp
Preclinical, Journal: Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma. (Pubmed Central) - Jan 12, 2022
Our results indicate that employing IgA GD2 as a novel isotype has two major benefits: it halts antibody-induced excruciating pain and improves neutrophil-mediated lysis of neuroblastoma. Thus, we postulate that patients with high-risk neuroblastoma would strongly benefit from IgA GD2 therapy.
- | Erwinase (erwinia L-asparaginase) / Jazz
Journal: l-Asparaginase and HCP quantification by SWATH LC-MS/MS for new and improved purification step in Erwinia chrysanthemil-asparaginase manufacture. (Pubmed Central) - Jan 12, 2022
Erwinase® or Erwinaze® are the proprietary names for the L-asparaginase enzyme derived from Erwinia chrysanthemi.L-asparaginase is an integral part of the treatment of Acute Lymphoblastic Leukaemia (ALL) in children and adolescents...The data quantified that L-asparaginase from the new process step was 2.28-fold higher in concentration than in legacy-process samples. The new step, using a modern ion exchanger, was at least equivalent and in some cases outperformed the legacy resin step in terms of HCP clearance for 78.2% of total HCPs (528 of 675 total proteins).
- | PRI-724 / PRISM Pharma, Ohara Pharma
Journal: The Small-Molecule Wnt Inhibitor ICG-001 Efficiently Inhibits Colorectal Cancer Stemness and Metastasis by Suppressing MEIS1 Expression. (Pubmed Central) - Jan 12, 2022
Collectively, our findings suggest that ICG-001 efficiently inhibits CRC stemness and metastasis by suppressing MEIS1 expression. These results provide a basis for the further clinical investigation of ICG-001 as a targeted therapy for CSCs, opening a new avenue for the development of novel Wnt inhibitors for the treatment of CRC metastasis.
- || JPH203 - J / Pharma
Review, Journal: Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways. (Pubmed Central) - Jan 12, 2022
In addition, JPH203, which is a selective LAT1 inhibitor, has shown excellent inhibitory effects on the proliferation in a variety of tumor cells. The current phase I clinical trials of JPH203 in patients with biliary tract cancer have also achieved good results, which is the future research direction for LAT1 targeted therapy drugs.
- | Amnolake (tamibarotene) / TMRC, Syros, Nippon Shinyaku, Zeria Pharma
Journal: Combination of a synthetic retinoid and a DNA demethylating agent induced differentiation of neuroblastoma through retinoic acid signal reprogramming. (Pubmed Central) - Jan 11, 2022
The current phase I clinical trials of JPH203 in patients with biliary tract cancer have also achieved good results, which is the future research direction for LAT1 targeted therapy drugs. Epigenetic drug-based differentiation therapy using 5-aza-dC and TBT is a promising strategy for refractory NBLs.
- | ZSTK474 / Zenyaku Kogyo
Journal, PD(L)-1 Biomarker, IO biomarker: Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. (Pubmed Central) - Jan 7, 2022
Epigenetic drug-based differentiation therapy using 5-aza-dC and TBT is a promising strategy for refractory NBLs. PI3K inhibitor in the combination with ICB with the optimized protocol fine-tuned T cell activation signaling for antitumor immunity via decreasing Tregs and optimizing memory CD8 T cell responses, illustrating a promising combination therapy.
- || Amnolake (retinobenzoic acid) / TMRC, Syros, Nippon Shinyaku, Zeria Pharma
Clinical, Journal: Defining the Transcriptional Control of Pediatric AML Highlights RARA as a Super-Enhancer Regulated Druggable Dependency. (Pubmed Central) - Jan 7, 2022
Tamibarotene prolonged 13 survival and suppressed the leukemia burden of a RARA SE-positive pAML patient-14 derived xenograft (PDX) mouse model compared to a RARA SE-negative PDX. Our work 15 demonstrates that examining chromatin regulation can identify new, druggable 16 dependencies in pAML and provides rationale for a pediatric tamibarotene trial in children 17 with RARA-high AML.
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp
Journal: G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment. (Pubmed Central) - Jan 6, 2022
Our work 15 demonstrates that examining chromatin regulation can identify new, druggable 16 dependencies in pAML and provides rationale for a pediatric tamibarotene trial in children 17 with RARA-high AML. Our preclinical data support the use of G-CSF as an alternative stimulating cytokine to GM-CSF in the treatment of high-risk neuroblastoma with dinutuximab, warranting further testing of G-CSF in a clinical setting.
- | PRI-724 / PRISM Pharma, Ohara Pharma
Journal: Linderapyrone: A Wnt signal inhibitor isolated from Lindera umbellata. (Pubmed Central) - Jan 6, 2022
cDNA microarray analysis in a linderapyrone derivative treated human colorectal cancer cells showed that this compound downregulates Wnt signaling pathway. Moreover, we successes to synthesize the derivative of linderapyrone that has stronger inhibitory effect than linderapyrone and ICG-001 (positive control).
- ||| Amnolake (tamibarotene) / Syros
Trial primary completion date: SELECT MDS-1: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 6, 2022
P3, N=190, Recruiting, Sponsor: Syros Pharmaceuticals
Moreover, we successes to synthesize the derivative of linderapyrone that has stronger inhibitory effect than linderapyrone and ICG-001 (positive control). Trial primary completion date: Jul 2023 --> Dec 2023
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date: NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Jan 5, 2022
P2, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2023 --> Dec 2023 Trial completion date: Dec 2021 --> Jan 2023
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Jan 5, 2022
P2, N=95, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Dec 2021 --> Jan 2023 Active, not recruiting --> Recruiting
- | paclitaxel / Generic mfg.
Journal: BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated β-catenin acetylation. (Pubmed Central) - Jan 4, 2022
Notably, treating with the ?-catenin/CBP inhibitor PRI-724 induced an enhancement of chemotherapeutic response of paclitaxel in BOP1-overexpressing TNBC cells. These findings indicate that BOP1 is involved in chemoresistance development and might serve as a prognostic marker and therapeutic target in TNBC.
- | JPH203 - J / Pharma
Journal: IL-18-Mediated SLC7A5 Overexpression Enhances Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells via the c-MYC Pathway. (Pubmed Central) - Jan 4, 2022
In conclusion, our results indicate that IL-18 promotes the osteogenic differentiation of hBMSCs via the SLC7A5/c-MYC pathway and, therefore, may play an important role in fracture healing. These findings will provide new treatment strategies for delayed fracture healing after splenectomy.
- | PRI-724 / PRISM Pharma, Ohara Pharma
Journal: Auranofin and ICG-001 Emerge Synergistic Anti-tumor Effect on Canine Breast Cancer by Inducing Apoptosis via Mitochondrial Pathway. (Pubmed Central) - Jan 4, 2022
Moreover, the synergistical effect was related with apoptosis caused by mitochondrial damage and ROS production. In conclusion, combination of AF and ICG-001 could synergistically suppress the growth of CBC in vitro and in vivo by leading apoptosis via mitochondrial signaling pathway and might provide a novel potential choice for the clinical treatment of CBC.
- | PRI-724 / PRISM Pharma, Ohara Pharma
Journal: Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency. (Pubmed Central) - Jan 1, 2022
The inhibitors GM6001, BB94, and ICG-001 suppressed the migration and invasion of cancer cells with ARID1A-deficiency. Our findings provide novel insights into the mechanism of ARID1A metastasis and offer a scientific basis for targeted therapy of ARID1A-deficient cancer cells.
- || niclosamide / Generic mfg.
Review, Journal: Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update. (Pubmed Central) - Jan 1, 2022
Significant progress has been made in inhibiting Wnt and thus stopping the progression of liver fibrosis by diminishing key components for its action. Comprehending the role of the Wnt signaling pathway in liver fibrosis may lead to discovery of novel targets in liver fibrosis therapeutic strategies' development.
- | Jevtana (cabazitaxel) / Sanofi, Emcure
Journal: Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer. (Pubmed Central) - Dec 30, 2021
Proteomic analysis of serum EVs was successfully accomplished by using Tim-4 as a tool to isolate highly purified EVs. Our results suggest that the combination use of CBZ and PI3K inhibitor could be a promising treatment option for CBZ-resistant PC patients.
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Trial completion date, Trial primary completion date: Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) (clinicaltrials.gov) - Dec 29, 2021
P1, N=12, Active, not recruiting, Sponsor: Kiminori Kimura, MD
Our results suggest that the combination use of CBZ and PI3K inhibitor could be a promising treatment option for CBZ-resistant PC patients. Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Dec 2021 --> May 2022
- | Unituxin (dinutuximab) / United Therapeutics Corp
Journal: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz et al. (Pubmed Central) - Dec 28, 2021
Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Dec 2021 --> May 2022 No abstract available
- | Unituxin (dinutuximab) / United Therapeutics Corp
Journal: Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora et al. (Pubmed Central) - Dec 28, 2021
No abstract available No abstract available
- || Unituxin (dinutuximab) / United Therapeutics Corp
Clinical, Review, Journal: Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients. (Pubmed Central) - Dec 25, 2021
Pain can be severe especially in the first courses of dinutuximab infusion, and requires the administration of gabapentin and continuous morphine infusion. This paper will focus on the incidence, mechanisms, characteristics, and treatment of neuropathic pain and peripheral neuropathy due to dinutuximab administration in neuroblastoma patients.
- | Unituxin (dinutuximab) / United Therapeutics Corp
Journal: Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2 breast cancer stem-like cells. (Pubmed Central) - Dec 21, 2021
Dinutuximab successfully eliminated GD2 cells and reduced tumor growth in both in vivo models. Our data provide proof-of-concept for the criticality of GD2 in BCSCs and demonstrate the potential of dinutuximab as a novel therapeutic approach for TNBC.
- paclitaxel / Generic mfg.
EXAMINATION OF WNT SIGNALING AS A THERAPEUTIC TARGET FOR PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) USING A PANCREATIC TUMOR ORGANOID LIBRARY (PTOL) ([VIRTUAL]) - Dec 17, 2021 - Abstract #APCM2021APCM_41;
The clinical utilization of this combinatory treatment modality in pancreatic cancer PDOs has thus far been supported in our patient-derived xenograft models treated with Wnt inhibitor plus paclitaxel or gemcitabine. WES and gene expression analysis of each organoid will be done as an additional avenue of analysis to comprehensively correlate genotype and Wnt (in)dependency observed in vitro.